Patients with symptomatic dermographism have spent years managing a condition where ordinary friction, a shirt collar, a scratched itch, triggers hives and burning, with nothing more than antihistamines that often fail to control symptoms. That gap closed on October 7, when the FDA approved remibrutinib (Rhapsido) specifically for adults with SD inadequately controlled by H1 antihistamines, based on data from the SD cohort of the Phase 3 RemIND trial.
The approval carries a structural quality worth noting for trial watchers: RemIND enrolled both CSU and SD cohorts under one protocol, letting Novartis pursue two regulatory submissions from a single study rather than running separate programs. That design paid off in under thirteen months. Rhapsido first cleared the FDA for chronic spontaneous urticaria on September 30, 2025, making remibrutinib the first BTK inhibitor approved for CSU. The SD approval followed in October 2026, making Rhapsido the only prescription treatment with approved indications in both conditions.
For trial sponsors designing programs in related mast-cell-driven skin conditions, the RemIND structure is worth examining as a model. Running parallel indication cohorts within a single Phase 3 study compresses the calendar between a first and second approval, but it also concentrates execution risk: a protocol hold or enrollment problem affects both cohorts at once. Novartis appears to have navigated that risk cleanly here. Remibrutinib is an oral, highly selective BTK inhibitor, and its mechanism targets the BTK-driven mast cell signaling that underlies both SD and CSU, which is likely what made the shared-protocol approach biologically defensible from the outset.
The concrete marker to track now is uptake among the antihistamine-refractory SD population, a group that historically had no approved oral option and has been managed through avoidance strategies and off-label approaches. Prescriber adoption in CSU over the past year will give Novartis a commercial infrastructure and physician familiarity that could shorten the ramp in SD considerably.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
